Shire's Wellhoefer On Genetic Disease R&D And Expanding Access To Medicines

 
• By Mandy Jackson

Scrip spoke with Shire's Head of Genetic Diseases, Medical Affairs, Hartmann Wellhoefer about upcoming milestones in the company's R&D pipeline and improving access to medicines for rare diseases after the Baxalta merger.

DNA detail background with selective focus

More from Business

More from Scrip